Oncolytic virus therapy for solid tumor is an well-established concept as a promising tumor treatment strategy. Oncolytic viruses, either naturally occurring or genetically engineered, have the ability to replicate and destroy tumor cells while sparing normal cells. The lysis of tumor cells triggers potent antitumor responses and mediates tumor regression at distant sites not exposed to the virus. In 2015, the U.S. Food and Drug Administration (FDA) approved the first Oncolytic virus (OV) therapy for the treatment of melanoma lesions in the skin and lymph nodes. Despite these advancements, there are still unresolved issues regarding virus selection, dosage, and optimal administration route.
The primary objective of this research topic is to monitor the latest developments in oncolytic virotherapy for solid tumors, including non-small cell lung cancer, gastric cancer, breast cancer, colorectal tumor, hepatic carcinoma, and others. The focus will be on the changes in both the immune microenvironment and immune cells induced by oncolytic virotherapy. Additionally, the research aims to discover novel oncolytic viruses or other combined therapies to enhance the safety and efficacy of oncolytic virotherapy.
The scope of this research topic is confined to the exploration of oncolytic virotherapy in solid tumors. We welcome articles addressing, but not limited to, the following themes:
- Engineering oncolytic viruses to stimulate anti-tumor immune responses more effectively.
- Appropriate animal models for validation of immune alterations in oncolytic virotherapy.
- Novel Delivery Systems for Immunotherapy.
- Combination therapy with oncolytic viruses and other immunotherapies in solid tumors.
- Combination therapy with oncolytic viruses and other adjuvant therapies (chemotherapy, radiotherapy, electric field therapy, conventional medical treatment, etc.) in solid tumors.
- Clinical study of oncolytic virotherapy.
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Oncolytic virus therapy for solid tumor is an well-established concept as a promising tumor treatment strategy. Oncolytic viruses, either naturally occurring or genetically engineered, have the ability to replicate and destroy tumor cells while sparing normal cells. The lysis of tumor cells triggers potent antitumor responses and mediates tumor regression at distant sites not exposed to the virus. In 2015, the U.S. Food and Drug Administration (FDA) approved the first Oncolytic virus (OV) therapy for the treatment of melanoma lesions in the skin and lymph nodes. Despite these advancements, there are still unresolved issues regarding virus selection, dosage, and optimal administration route.
The primary objective of this research topic is to monitor the latest developments in oncolytic virotherapy for solid tumors, including non-small cell lung cancer, gastric cancer, breast cancer, colorectal tumor, hepatic carcinoma, and others. The focus will be on the changes in both the immune microenvironment and immune cells induced by oncolytic virotherapy. Additionally, the research aims to discover novel oncolytic viruses or other combined therapies to enhance the safety and efficacy of oncolytic virotherapy.
The scope of this research topic is confined to the exploration of oncolytic virotherapy in solid tumors. We welcome articles addressing, but not limited to, the following themes:
- Engineering oncolytic viruses to stimulate anti-tumor immune responses more effectively.
- Appropriate animal models for validation of immune alterations in oncolytic virotherapy.
- Novel Delivery Systems for Immunotherapy.
- Combination therapy with oncolytic viruses and other immunotherapies in solid tumors.
- Combination therapy with oncolytic viruses and other adjuvant therapies (chemotherapy, radiotherapy, electric field therapy, conventional medical treatment, etc.) in solid tumors.
- Clinical study of oncolytic virotherapy.
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.